Biovie Inc.BIVI
Price (close)
$1.60
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$22.1M
Dividend yield
—
1-year total return
-10.8%
Net margin
—
Revenue growth
—
Debt / equity
—
What Biovie Inc. does.
or “our”) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative
of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceutical company and a related party in June 2021.
The acquired assets included NE3107 (“bezisterim”). Bezisterim, the approved generic name for NE3107 is an investigational,
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net income | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M |
More on BIVI.
- Biovie Inc. summary
- Biovie Inc. financial statements
- Biovie Inc. key metrics
- Biovie Inc. health scores and style box
- Biovie Inc. earnings
- Biovie Inc. dividends
- Biovie Inc. valuation
- Biovie Inc. ownership and insiders
- Biovie Inc. peers
Figures from Biovie Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.